Ganirelix
Ovarian Hyperstimulation Syndrome
Eugoniaprotein_peptidePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Ovarian Hyperstimulation Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hcg UConn Health | Phase 4 | BB |
Hcq Aljazeera Hospital | N/A | D |
Degarelix Bioroma | D | |
Cabergoline Etlik Zubeyde Hanim Womens' Health and Teaching Hospital | N/A | D |
Same molecule, other indications
Ganirelix is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →